World Journal of Gastroenterology

Online Submissions: http://www.wjgnet.com/1007-9327office
wjg@wjgnet.com
doi:10.3748/wjg.v17.i16.2070

World J Gastroenterol 2011 April 28; 17(16): 2070-2075
ISSN 1007-9327 (print) ISSN 2219-2840 (online)

EDITORIAL

Optimizing management in autoimmune hepatitis with liver failure at initial presentation

Jonathan R Potts, Sumita Verma

Jonathan R Potts, Sumita Verma, Department of Medicine, Brighton and Sussex Medical School, Brighton, BN1 9PX, United Kingdom
Author contributions: Verma S conceived the idea; Potts JR performed the literature search; Verma S wrote the initial draft; Potts JR and Verma S contributed equally to writing the final draft of the manuscript.
Correspondence to: Dr. Sumita Verma, Senior Lecturer Medicine, Honorary Consultant Hepatologist, Department of medcine Brighton and Sussex Medical School, Falmer, Department of medcine Brighton, BN1 9PX,
United Kingdom. s.verma@bsms.ac.uk
Telephone: +44-1273-877890 Fax: +44-1273-877576
Received: October 12, 2010 Revised: November 4, 2010
Accepted: November 11, 2010
Published online: April 28, 2011

Abstract

Autoimmune hepatitis (AIH) is a disease of unknown etiology, its hallmark being ongoing hepatic inflammation. By its very nature, it is a chronic condition, although increasingly, we are becoming aware of patients with acute presentations, some of whom may have liver failure. There are very limited published data on patients with AIH with liver failure at initial diagnosis, which consist mostly of small retrospective studies. As a consequence, the clinical features and optimal management of this cohort remain poorly defined. A subset of patients with AIH who present with liver failure do respond to corticosteroids, but for the vast majority, an urgent liver transplantation may offer the only hope of long-term survival. At present, there is uncertainty on how best to stratify such a cohort into responders and non- responders to corticosteroids as soon as possible after hospitalization, thus optimizing their management. This editorial attempts to answer some of the unresolved issues relating to management of patients with AIH with liver failure at initial presentation. However, it must be emphasized that, at present, this editorial is based mostly on small retrospective studies, and it is an understatement that multicenter prospective studies are urgently needed to address this important clinical issue.

Key words: Autoimmune hepatitis; Liver failure; Liver transplantation; Corticosteroids

Peer reviewer: Atsushi Tanaka, MD, PhD, Associate Professor, Department of Medicine, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo 173-8605, Japan

Potts JR, Verma S. Optimizing management in autoimmune hepatitis with liver failure at initial presentation. *World J Gastroenterol* 2011; 17(16): 2070-2075 Available from: URL: http://www.wjgnet.com/1007-9327/full/v17/i16/2070.htm DOI: http://dx.doi.org/16.3748/wjg.v17.i16.2070

INTRODUCTION

Autoimmune hepatitis (AIH) is a disease that is characterized by chronic hepatic inflammation, presence of autoantibodies [antinuclear antibody (ANA), anti-smooth muscle antibody (SMA), and liver kidney microsomal (LKM) antibody], female preponderance and elevated serum gammaglobulins, especially IgG[1]. Earlier studies have established the beneficial effects of corticosteroids in AIH and up to 80% of patients can now achieve remission with immunosuppressants[2,3]. At accession, 10%-20% of patients with AIH can be negative for the conventional autoantibodies[4], although their outcomes, especially response to immunosuppression, are no different from those that are autoantibody-positive[5].

AIH can have protean manifestations, with the majority of patients presenting with subclinical or chronic disease. However, in > 25%, the disease may present acutely with jaundice, a subset of whom may have fulminant or subacute liver failure (LF)[6-8]. Fulminant hepatic failure (FHF) is a devastating clinical condition that occurs in patients

with no prior history of liver disease, and is characterized by development of hepatic encephalopathy and coagulopathy within 8 wk after onset of jaundice[9]. In contrast, those with subacute LF present with encephalopathy at 8-26 wk after onset of symptoms[10]. In a survey in the United States carried out between 1998 and 2008, the major etiologies of FHF in 1147 patients were acetaminophen overdose (46%), followed by indeterminate causes (14%), drug-induced (11%), hepatitis B virus (7%), other causes (7%), AIH (5%), ischemic hepatitis (4%), hepatitis A virus (3%) and Wilson's disease (2%)[11]. Similar data were reported from Europe where 2%-5% of patients with FHF have AIH as the underlying etiology[12,13]. Unfortunately, neither the International Autoimmune Hepatitis Group (IAIHG) criteria[14] nor the simplified diagnostic criteria for diagnosis of AIH[15] have been extensively validated in patients with LF; largely because of the small number of cases encountered. Thus, diagnosis of AIH and LF remains clinical and is supported by positive autoantibodies, negative viral serology, absence of alcohol excess and culprit drugs, and compatible liver biopsy. This has been corroborated by an earlier study in which 28 patients with FHF were clinically diagnosed with AIH, but after application of the IAIHG criteria and simplified scoring systems only 50% and 46%, respectively, fulfilled the criteria, with the concordance of the two scoring systems being only 46%[16].

Immunoparesis is commonly seen in critically ill patients with LF in whom both autoantibodies and/or elevated IgG concentrations may be absent[17]. In addition, because of the severity of the hepatic insult (massive/submassive necrosis), histological evaluation may be difficult or impossible[16]. Although challenging, AIH can still be diagnosed in such a scenario by excluding other liver diseases, and by testing for other autoantibodies [perinuclear antineutrophil cytoplasmic antibodies (pANCA), and antibodies to soluble liver antigen (SLA)][18,19]. Furthermore, if the patient is HLA B8, DR3 or DR4 positive, has a concurrent immunological disorder, and responds to corticosteroid therapy, this further lends credence to the diagnosis of AIH[4]. Nonetheless, the decision to initiate corticosteroids in patients who do not fulfill conventional diagnostic criteria for AIH must be made on an individual basis, and remains the prerogative of the treating hepatologist.

AIH AND LF

There is a paucity of published data on patients with AIH with LF at initial diagnosis; consisting mostly of anecdotal case reports or small case series[20,21]. Thus the clinical characteristics, response to immunosuppression, and outcomes with/without liver transplantation (LT) of this cohort remain poorly described. Much of the controversy hinges on a critical management issue, namely should such patients be given a trial of corticosteroids, be priority listed for LT, or both. If corticosteroids are indeed initiated, how and at what time point do we define failure of medical treatment? This editorial attempts to address some of these controversies with the aim to develop strategies that could optimize management of patients with AIH that present with LF.

We therefore searched the medical literature (PubMed) to collect published data on AIH with initial presentation with LF. Only studies providing data on type and duration of immunosuppressive therapy and outcomes were included. Case reports/small case series, and studies in which authors reported acute AIH in the absence of LF were excluded. We identified five studies that met our inclusion criteria and these included a total of 85 patients with AIH and LF[7,22-25] (Table 1). In three of the five studies[7,23,24], patients were diagnosed with AIH according to IAIHG criteria, although information regarding probable or definite AIH was only available in two[7,24]. In the remaining two studies[22,25], the diagnosis of AIH was based on the presence of autoantibodies, elevated IgG levels, exclusion of Wilson's disease, negative viral serology, absence of culprit drugs, and compatible liver histology (1). The patients were very heterogeneous as regards ethnicity, presence/absence of cirrhosis, and inclusion of acute and subacute LF. It is well known that these factors have a prognostic value in patients with AIH and in those with LF[7,26-28]. In addition, all the studies were retrospective, and one has only been published in an abstract form[22]. Nonetheless, these five studies do provide valuable information about the natural history of AIH with LF at initial presentation.

In these five studies, the prevalence of LF at initial presentation in patients with AIH varied from 8.7% to 19.8%[7,23]. In all but one patient this was the first presentation of their disease. The majority (> 75%) were women in the third to the sixth decade with type 1 AIH. Almost all patients had either encephalopathy at admission and/or had significant coagulopathy (Table 1). IgG levels were available in two studies[24,25], and 74% had levels in excess of 1800 mg/dL.

OUTCOMES IN PATIENTS WITH AIH AND LF

Table 2 shows treatment data and outcomes in these five above studies. Of the total of 85 patients, 69 (89.2%) received immunosuppression, mostly corticosteroids (Table 2). For the majority of the patients, there was no rationale provided for initiation or withholding corticosteroids, and the decision appeared to have been made on an *ad hoc* basis. The remission rates with immunosuppression varied from 8.3% to 50% (average: 33.3%, 23/69) (Table 2). Overall, 43.5% (37/85) either underwent or were listed for LT and 32.9% (28/85) died. These outcomes are certainly poorer than those reported in patients with chronic AIH (remission with corticosteroids ~80%[2,3], need for LT 1.4%-8.4% and mortality 1.8%-4.9%[27,29]), and makes for dismal reading.

The variability in remission rates with corticosteroid therapy in these five studies is most certainly a reflection of the heterogeneous patient population. Unsurprisingly, the lowest remission rates were seen in the study of Ichai *et al*[25], which had the sickest patients, as reflected by their high admission MELD scores. However, those patients with AIH and LF that did respond to corticosteroid

Table 1 Clinical characteristics of patients with autoimmune hepatitis with liver failure at initial presentation

	Villamil *et al*[22][1] (*n* = 28)	Kessler *et al*[23] (*n* = 10)	Miyake *et al*[24] (*n* = 11)	Ichai *et al*[25] (*n* = 16)	Verma *et al*[7] (*n* = 20)
Study design	Retrospective	Retrospective	Retrospective	Retrospective	Retrospective
Age (yr)[2]	41	40 ± 15.9	53 (16-75)	36 ± 13.1	41.3 ± 14.2
Definition of LF	NA	NA	PT < 40% and HE ⩾ grade 2	HE within 12 wk of jaundice	Any grade HE and/or INR > 2
Symptoms duration[2]	NA	3.2 wk	24 (16-52) d	NA	2.1 ± 2.5 mo[3]
Female	NA	8 (80%)	11 (100%)	14/16 (87.5%)	15 (75%)
Ethnicity or country of origin	South American	80% White	Japanese	French	70% black
Definite/probable AIH (IAIHG[4] criteria)	NA	NA[5]	3(36%)/8 (64%)	NA	9(45%)/11(55%)
LC/LKM[6] positive	6 (21.4)	1 (10%)		3 (18.7%)	NA
ANA/SMA[7] positive	22 (78.5%)	7 (70%)	NA	11 (68.7%)	20 (100%)
Bilirubin[2] (mg/dL)	398[8]	16.97 ± 9.83	20.6 (5.9-31)	425 (278-850)[8]	19.3 ± 10.3
AST or ALT[2]	NA	1179 ± 1127.17	220 (59-1094)	678 (60-2867)	1147.1 ± 711.4
INR[2] or PT	30%	49.3 ± 66.9	29% (6%-38%)	5.36 (1.7-12.2)	2.7 ± 1.4
HE[9] at onset	28 (100%)	8 (80%)	11 (100%)	10 (62.5%)	19 (95%)
Cirrhosis	None	2/10 (20%)	NA	None	8/20 (40%)
MELD[2]	NA	NA	NA	37 (24-47)	28 ± 7.41
Sub-massive or massive necrosis (SMN, MN)	19/23 (82.6%) 17 needed LT and/or died	5/10 (50%)	NA	16/16 (100%) 15 needed LT and/or died	12/19 (63.1%), 10 needed LT and or died
Immunosuppressant regimen used	Prednisone 60 mg/d	Corticosteroids (Dose NA) and other[10]	Prednisolone 40-60 mg/d and steroid pulse	Prednisone 1 mg/kg per day and other[10]	Corticosteroids[11] 20-1250 mg/d
Poor prognostic criteria	1: PT < 20%; 2: Grade 4 HE; 3: SMN at diagnosis; 4: 20% increase in PT at day 3 of steroids	NA	1: High bilirubin at onset; 2: Worsening bilirubin during days 8-15 of steroid therapy	NA	1: Absence of cirrhosis; 2: MELD > 28; 3: Worsening trend in bilirubin and INR after 3.7 ± 0.6 d of steroid therapy
Septic events	NA	NA	NA	7 (43.7%), of whom 6 had received steroids	2 (10%), of whom 1 received steroids

[1]Published only in abstract form; [2]Data presented as mean ± SD or median (range); [3]Duration from first symptom (and not necessarily jaundice/hepatic encephalopathy) to hospitalization; [4]IAIHG: International Autoimmune Hepatitis Group; [5]Met IAIHG criteria, data on probable or definite disease unavailable; [6]LKM/LC: Liver kidney microsomal antibody/liver cytosol antibody; [7]ANA/SMA: antinuclear antibody/anti-smooth muscle antibody; [8]Values in μmol/L; [9]HE: Hepatic encephalopathy; [10]Additional immunosuppression was used in nine patients in the study of Kessler *et al* (azathioprine, tacrolimus, mycophenolate mofetil, 6-mercaptopurine, cyclosporine) and in one patient in the study of Ichai *et al* (azathioprine and cyclosporine); [11]Included prednisone, hydrocortisone and methylprednisone, (converted to equivalent doses of prednisone); LT:Liver transplantation; PT: Prothrombin time; AIH: Autoimmune hepatitis.

therapy survived, obviating the need for a subsequent LT. Unfortunately, among the non-responders to corticosteroids in these five studies (n = 46), death was the inevitable outcome in the absence of LT (Table 2). The duration of steroid therapy prior to death was highly variable (3-95 d). Clearly, in some, the illness was so fulminant that death occurred rapidly after hospitalization, thereby precluding LT, and in others, there were active contraindications to transplantation, such as sepsis (Table 2). Nevertheless, in these five studies, there were a subset of patients with AIH and LF in whom death may have been preventable had LT been more aggressively pursued. It is conceivable that initiation of steroids provided a false sense of security, thereby delaying transplant evaluation.

One could argue that the low remission rates to corticosteroids in this cohort were partly related to delay in initiating therapy. However, where available, the data do not support this conclusion, as corticosteroids were initiated promptly, especially in the sicker patients. In our study, subsequent non-responders to corticosteroids were commenced on therapy within 2.6 ± 1.8 d of admission, compared to 6.4 ± 5.5 d in those who eventually responded to corticosteroids[7]. It is more likely that non-responders to corticosteroids had aggressive disease at the time of diagnosis with a critical degree of liver cell death already having occurred prior to the introduction of medical treatment[24]. This hypothesis is supported by the study of Ichai *et al*[25], in which all patients had massive/sub-massive liver necrosis (median MELD score at admission: 37), with only 8.3% responding to corticosteroids and > 80% needing LT.

OPTIMIZING MANAGEMENT IN PATIENTS WITH AIH AND LF

Assessing patients with LF for LT is a complex process. The most widely used criteria for prioritizing patients for LT are the King's College criteria[30]. However, neither the King's College criteria[29] nor the more recently developed MELD score[31] have been validated in patients with AIH and LF. This is most likely due to the fact that the prevalence of AIH in patients with LF being evaluated for LT is low (0%-5%)[12,13,32]. As is evident from the published data[7,22-25], there certainly are a subset of patients with AIH and LF who will respond to corticosteroids. Inappropri-

Table 2 Outcomes of patients with autoimmune hepatitis and initial presentation with liver failure

Study	Villamil *et al*[22] (*n* = 28)	Kessler *et al*[23] (*n* = 10)	Miyake *et al*[24] (*n* = 11)	Ichai *et al*[25] (*n* = 16)	Verma *et al*[7] (*n* = 20)
Treated with IS[1]	25	10	8	12	14
Responders to steroids	9 (36%) (alive)	4 (40%) (alive)	2 (25%) (alive)	1 (8.3%) (alive)	7 (50%) (alive)
Non responders	16	6	6	11	7
LT	11 (2 Died)	3	1	10 (1 Died)	1 (Died)
Listed for LT	-	1	-	-	1 (Died)
Died without LT	5	2	5	1[4]	5[2]
Not treated with IS[1]	3	-	3[3]	4	6
Spontaneous survival	-	-	3	-	-
LT	1	-	-	3	5 (1 Died)
Listed for LT	-	-	-	-	-
Died	2	-	-	1	1
Overall underwent LT or listed for LT	12/28 (42.8%)	4/10 (40%)	1/11 (9%)	13/16 (81.2%)	7/20 (35%)
Overall mortality	9/28 (32.1%)	2/10 (20%)	5/11 (45.4%)	3/16 (18.7%)	9/20 (45%)

[1]IS: Immunosuppression; [2]Four died while being evaluated for liver transplantation, in 1 sepsis precluded liver transplantation evaluation; [3]Treated with plasmapheresis and or stronger neo-minophagen; [4]Not evaluated for LT due to sepsis; LT: Liver transplantation. Additional outcome data obtained by personal communication with authors.

ate transplantation in such patients would mean subjecting them to unnecessary surgery (and its attendant complications) and lifelong immunosuppression. In addition, it would deprive another more suitable recipient from receiving the graft[33]. On the other hand, denying LT to a patient with AIH and LF who is unlikely to respond to corticosteroids means condemning them to a certain death, which is unacceptable, especially since post-transplant survival for AIH is excellent [estimated 5-year survival probability after first LT is 0.73 (95% CI: 0.67-0.77)][34].

The contentious issue thus is how best to stratify patients with AIH and LF into likely responders and non-responders to corticosteroids as soon as possible after hospitalization; hence optimizing their management. In our study[7], all responders to corticosteroid therapy had a MELD score ⩽ 28 at admission. This is also supported by Ichai *et al*[25], who showed that the only patient to respond to corticosteroids had a MELD score of 24, and none with an initial MELD score > 28 responded to corticosteroids. Furthermore, in our study, responders to corticosteroids were more likely to have either an improvement or stabilization in bilirubin and INR within 3.7 ± 0.6 d of initiation of corticosteroid therapy, whereas non-responders tended to have a trend for higher bilirubin and INR[7]. Villamil *et al*[22] also observed that a 20% increase in prothrombin time (PT) at day 3 of corticosteroid therapy to be a predictor of poor outcome, along with PT < 20% , grade 4 encephalopathy, and LKM antibody/liver cytosol (LC) antibody positivity at diagnosis. Histological evidence of sub-massive/massive necrosis is also invariably associated with need for LT and/or death (Table 1). Surprisingly, in our study, the presence of cirrhosis was more likely was associated with response to corticosteroids[7]. Although the impact of cirrhosis on the natural history of AIH remains controversial[27,28,35,36], it is likely that this group has long-standing indolent disease that progresses to cirrhosis, with LF representing an acute relapse of AIH[37]. This is in contrast with the study of Ichai *et al*[25], in which absence of significant hepatic fibrosis in all the patients indicated a *de novo* fulminant disease process.

CORTICOSTEROIDS AND INFECTIONS

Whether steroids increase the risk of septic complications in patients with severe liver disease is subject to an ongoing debate. The issue becomes even more contentious in the presence of LF because in itself that has been associated with an increased risk of bacterial and fungal infections[25,38,39]. In fact, earlier studies have shown that up to 35% of patients with LF can develop bacteremia in the pre-transplant period[39]. This increased propensity for sepsis is further aggravated in the post-transplant setting due to use of immunosuppression. Therefore, not surprisingly, sepsis with or without multiorgan failure, accounts for almost one-third of all deaths in patients undergoing LT for LF, and is the most common cause of mortality in this cohort[40]. In the study of Ichai *et al*[25] (which had the sickest cohort of patients with a median MELD score of 37 at admission), 42.3% developed a septic event, and this prevalence is not higher than that reported previously[39]. It is however noteworthy that in Ichai *et al*'s study septic events were more likely to occur in those initiated (6/12) versus those not initiated (1/4) on corticosteroids[25]. It is unclear whether patients received prophylactic antibiotics in this study. Reich *et al*[41] also have reported an increased trend for wound infection in corticosteroid-treated patients with AIH undergoing LT (30.7% *vs* 5.2%). In a recent publication that analyzed data from the European Transplant Registry, in comparison with transplantation for primary biliary cirrhosis and alcoholic cirrhosis, the probability of infectious complications limiting patient survival was significantly increased after transplantation for AIH. This was especially relevant to patients aged > 50 years and within the first 3 mo of transplantation[34]. Unfortunately, data on disease severity and use of pre-transplant immunosuppression and prophylactic antibiotics were not available in that study. On the other hand, others have reported corticosteroids not to be associated with increased risk of infections in patients with severe AIH[42]. These discordant results most likely reflect the heterogeneous patient groups (in-

cluding the whole spectrum from chronic disease to FHF), use of varying immunosuppressive regimens, and inconsistent use of prophylactic antibiotics. Nonetheless, Ichai *et al*[25] caution against injudicious use of corticosteroids in patients with AIH and LF, and on the contrary, emphasize the need for expedited LT evaluation in such a cohort. Furthermore, it lends credence to the argument for the use of prophylactic antibiotics and antifungal agents, because such a strategy has been shown to reduce the risk of infections in the pre-transplant setting[43].

THE FUTURE

Prospective multicenter studies are clearly needed to address this complex and important clinical issue. In future, testing for additional autoantibodies and HLA typing might also help risk-stratify patients. For example, presence of antibodies to SLA have been associated with DRB1 *0301, and such patients have aggressive disease and are more likely to require LT and/or die[44,45].

CONCLUSION

The diagnosis and management of patients with AIH with AF at initial diagnosis can be challenging. Although there are only limited published data available, mostly in the form of small retrospective studies, up to 8.7%-19.8% of patients with AIH may have this form of presentation. On the whole, about one-third can respond to corticosteroids and have a good outcome, although for the vast majority, LT may offer the only hope of long-term survival. A MELD score at admission of $\leqslant$ 28, more severe hepatic fibrosis, absence of sub-massive/massive necrosis, and early (within 4 d) improvement or stabilization in bilirubin and INR, identify those who are likely to respond to corticosteroid therapy, and thus survive without the need for LT. If clinical and biochemical improvement does not occur within the first few days, then continuation of corticosteroids may be a futile exercise, as it would be unlikely to change the clinical outcome, and on the contrary, may result in adverse events, especially sepsis. Nonetheless, if a decision is made to continue therapy with corticosteroids it is imperative that LT be actively pursued concomitantly. Furthermore, it may not be unreasonable to consider prophylactic antimicrobial and antifungal agents in such high-risk patients. It must however be emphasized that, at present, these recommendations are based on small retrospective studies. This underlines the urgent need for prospective multicenter studies to address this important clinical issue.

ACKNOWLEDGEMENTS

SV is grateful to Dr. Villamil, Dr. Kessler and Dr. Miyake for providing additional data upon request.

REFERENCES

1 **Czaja AJ**, Freese DK. Diagnosis and treatment of autoimmune hepatitis. *Hepatology* 2002; **36**: 479-497
2 **Murray-Lyon IM**, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. *Lancet* 1973; **1**: 735-737
3 **Soloway RD**, Summerskill WH, Baggenstoss AH, Geall MG, Gitnićk GL, Elveback IR, Schoenfield LJ. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. *Gastroenterology* 1972; **63**: 820-833
4 **McFarlane IG**. Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. *Clin Liver Dis* 2002; **6**: 605-621
5 **Czaja AJ**, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. *Mayo Clin Proc* 1990; **65**: 23-30
6 **Ferrari R**, Pappas G, Agostinelli D, Muratori P, Muratori L, Lenzi M, Verucchi G, Cassani F, Chiodo F, Bianchi FB. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. *QJM* 2004; **97**: 407-412
7 **Verma S**, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. *Hepatology* 2007; **46**: 1828-1835
8 **Verma S**, Maheshwari A, Thuluvath P. Liver failure as initial presentation of autoimmune hepatitis: clinical characteristics, predictors of response to steroid therapy, and outcomes. *Hepatology* 2009; **49**: 1396-1397
9 **Trey C**, Davidson LS. The management of fulminant hepatic failure. In: Popper H, Schaffner F, editors. Progress in liver disease. New York: Grune and Stratton, 1970: 282-298
10 **Gimson AE**, O'Grady J, Ede RJ, Portmann B, Williams R. Late onset hepatic failure: clinical, serological and histological features. *Hepatology* 1986; **6**: 288-294
11 **Lee WM**, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: Summary of a workshop. *Hepatology* 2008; **47**: 1401-1415
12 **Escorsell A**, Mas A, de la Mata M. Acute liver failure in Spain: analysis of 267 cases. *Liver Transpl* 2007; **13**: 1389-1395
13 **Brandsaeter B**, Höckerstedt K, Friman S, Ericzon BG, Kirkegaard P, Isoniemi H, Olausson M, Broome U, Schmidt L, Foss A, Bjøro K. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the nordic countries. *Liver Transpl* 2002; **8**: 1055-1062
14 **Alvarez F**, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. *J Hepatol* 1999; **31**: 929-938
15 **Hennes EM**, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW. Simplified criteria for the diagnosis of autoimmune hepatitis. *Hepatology* 2008; **48**: 169-176
16 **Yeoman AD**, Westbrook RH, Al-Chalabi T, Carey I, Heaton ND, Portmann BC, Heneghan MA. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. *Hepatology* 2009; **50**: 538-545
17 **Gregorio GV**, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, Mowat AP, Vergani D, Mieli-Vergani G. Autoimmune hepatitis in childhood: a 20-year experience. *Hepatology* 1997; **25**: 541-547
18 **Mulder AH**, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. *Hepatology* 1993; **17**: 411-447

19 **Han S**, Tredger M, Gregorio GV, Mieli-Vergani G, Vergani D. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. *Hepatology* 1995; **21**: 58-62
20 **Viruet EJ**, Torres EA. Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis. *P R Health Sci J* 1998; **17**: 297-300
21 **Herzog D**, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. *J Hepatol* 1997; **27**: 578-582
22 **Villamil AG**, Casciato P, Eduardo M, Bustos D, Giunta D, Ciardullo M, et al. Fulminant autoimmune hepatitis type 1: Clinical presentation, outcome and prognostic factors. (Abstract 480) *AJT* 2005; **5** (Suppl 11): 278
23 **Kessler WR**, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. *Clin Gastroenterol Hepatol* 2004; **2**: 625-631
24 **Miyake Y**, Iwasaki Y, Terada R, Onishi T, Okamoto R, Sakai N, Sakaguchi K, Shiratori Y. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. *Aliment Pharmacol Ther* 2006; **23**: 1347-1353
25 **Ichai P**, Duclos-Vallée JC, Guettier C, Hamida SB, Antonini T, Delvart V, Saliba F, Azoulay D, Castaing D, Samuel D. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. *Liver Transpl* 2007; **13**: 996-1003
26 **O'Grady JG**, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. *Lancet* 1993; **342**: 273-275
27 **Verma S**, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. *Am J Gastroenterol* 2004; **99**: 1510-1516
28 **Roberts SK**, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. *Gastroenterology* 1996; **110**: 848-857
29 **Montano-Loza AJ**, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. *Hepatology* 2007; **46**: 1138-1145
30 **O'Grady JG**, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. *Gastroenterology* 1989; **97**: 439-445
31 **Kamath PS**, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. *Hepatology* 2001; **33**: 464-470
32 **Gow PJ**, Jones RM, Dobson JL, Angus PW. Etiology and outcome of fulminant hepatic failure managed at an Australian liver transplant unit. *J Gastroenterol Hepatol* 2004; **19**: 154-159
33 **Bernal W**, Auzinger G, Dhawan A, Wendon J. Acute liver failure. *Lancet* 2010; **376**: 190-201
34 **Schramm C**, Bubenheim M, Adam R, Karam V, Buckels J, O' Grady JG, Jamieson N, Pollard S, Neuhaus P, Manns MM, Porte R, Castaing D, Paul A, Traynor O, Garden J, Friman S, Ericzon BG, Fischer L, Vitko S, Krawczyk M, Metselaar HJ, Foss A, Kilic M, Rolles K, Burra P, Rogiers X, Lohse AW. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. *Liver Transpl* 2010; **16**: 461-469
35 **Verma S**, Redeker A. In type 1 autoimmune hepatitis, is cirrhosis at presentation or follow-up associated with a poorer outcome? *Hepatology* 2005; **42**: 1237; author reply 1237-1238
36 **Feld JJ**, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. *Hepatology* 2005; **42**: 53-62
37 **Nikias GA**, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. *J Hepatol* 1994; **21**: 866-871
38 **Rolando N**, Harvey F, Brahm J, Philpott-Howard J, Alexander G, Casewell M, Fagan E, Williams R. Fungal infection: a common, unrecognised complication of acute liver failure. *J Hepatol* 1991; **12**: 1-9
39 **Karvellas CJ**, Pink F, McPhail M, Cross T, Auzinger G, Bernal W, Sizer E, Kutsogiannis DJ, Eltringham I, Wendon JA. Predictors of bacteraemia and mortality in patients with acute liver failure. *Intensive Care Med* 2009; **35**: 1390-1396
40 **Kolber MA**, Hill P. Vincristine potentiates cytochalasin B-induced DNA fragmentation in vitro. *Cancer Chemother Pharmacol* 1992; **30**: 286-290
41 **Reich DJ**, Fiel I, Guarrera JV, Emre S, Guy SR, Schwartz ME, Miller CM, Sheiner PA. Liver transplantation for autoimmune hepatitis. *Hepatology* 2000; **32**: 693-700
42 **Ahmed M**, Mutimer D, Hathaway M, Hubscher S, McMaster P, Elias E. Liver transplantation for autoimmune hepatitis: a 12-year experience. *Transplant Proc* 1997; **29**: 496
43 **Rolando N**, Wade JJ, Stangou A, Gimson AE, Wendon J, Philpott-Howard J, Casewell MW, Williams R. Prospective study comparing the efficacy of prophylactic parenteral antimicrobials, with or without enteral decontamination, in patients with acute liver failure. *Liver Transpl Surg* 1996; **2**: 8-13
44 **Czaja AJ**, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. *Am J Gastroenterol* 2002; **97**: 413-4139
45 **Ma Y**, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B, Underhill J, Dürr R, Mieli-Vergani G, Vergani D. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. *Hepatology* 2002; **35**: 658-664

S- Editor Tian L **L- Editor** Kerr C **E- Editor** Ma WH